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In 2009 the ﬁrst European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guideline
for diagnosing Clostridium difﬁcile infection (CDI) was launched. Since then newer tests for diagnosing CDI
have become available, especially nucleic acid ampliﬁcation tests. The main objectives of this update of
the guidance document are to summarize the currently available evidence concerning laboratory diag-
nosis of CDI and to formulate and revise recommendations to optimize CDI testing. This update is
essential to improve the diagnosis of CDI and to improve uniformity in CDI diagnosis for surveillance
purposes among Europe. An electronic search for literature concerning the laboratory diagnosis of CDI
was performed. Studies evaluating a commercial laboratory test compared to a reference test were also
included in a meta-analysis. The commercial tests that were evaluated included enzyme immunoassays
(EIAs) detecting glutamate dehydrogenase, EIAs detecting toxins A and B and nucleic acid ampliﬁcation
tests. Recommendations were formulated by an executive committee, and the strength of recommen-
dations and quality of evidence were graded using the Grades of Recommendation Assessment, Devel-
opment and Evaluation (GRADE) system. No single commercial test can be used as a stand-alone test for
diagnosing CDI as a result of inadequate positive predictive values at low CDI prevalence. Therefore, the
use of a two-step algorithm is recommended. Samples without free toxin detected by toxins A and B EIA
but with positive glutamate dehydrogenase EIA, nucleic acid ampliﬁcation test or toxigenic culture results
need clinical evaluation to discern CDI from asymptomatic carriage. M.J.T. Crobach, CMI 2016;22:S63
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The previous European Society of Clinical Microbiology and In-
fectious Diseases (ESCMID) guidance document for Clostridium
difﬁcile infection (CDI) was published in 2009 [1]. Since then many
laboratories in Europe have implemented a diagnostic algorithm
for diagnosing CDI. However, many new diagnostic tests haveMedical Microbiology, Centre
ntre, PO Box 9600, 2300 RC
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).become available in the meantime, especially nucleic acid ampli-
ﬁcation tests (NAATs). Although several of these tests have been
marketed, their role in the diagnosis of CDI needs to be clariﬁed.
Also, the importance of free toxin detection in stool needs to be
addressed. This update of the previous guidance document is
essential to improve the diagnosis of CDI; to optimize its manage-
ment, prevention and control; and to improve uniformity in CDI
diagnosis for surveillance purposes across Europe.
The main objectives of this guidance document are to sum-
marize the currently available evidence concerning laboratory
diagnosis of CDI and to formulate recommendations to optimize
CDI testing. This guideline is intended for use among medical
microbiologists, gastroenterologists, infectious disease specialistsof Clinical Microbiology and Infectious Diseases. This is an open access article under
M.J.T. Crobach et al. / Clinical Microbiology and Infection 22 (2016) S63eS81S64and infection control practitioners. The target population is diar-
rhoeal patients suspected of having CDI.Material and Methods
To be able to revise our previous recommendations, an update of
the 2009 meta-analysis was performed. In addition, other guide-
lines and recent literature concerning the diagnosis of CDI were
reviewed.Update of meta-analysis
Search strategy
Studies evaluating laboratory assays for diagnosing CDI were
searched in PubMed, Embase, Web of Science, Central and the
Cochrane Library. Searches were performed in June 2014 with the
support of a trained librarian. The search was restricted to articles
published since 2009 in the English language. Meeting abstracts
were excluded. The search strategy is displayed in Supplementary
Material 1.Table 1
The 2  2 table used to calculate test characteristics
Diseased or reference
test positive
Not diseased or
reference test negative
Index test positive (a) True positive (b) False positive
Index test negative (c) False negative (d) True negativeReference tests
A reference test is the best available test and is the standard
against which other assays are compared. Cell cytotoxicity
neutralization assay (CCNA) and toxigenic culture (TC) are regarded
as reference tests for diagnosing CDI [2].
CCNA demonstrates the presence of free toxin B. For this test,
stool ﬁltrates are inoculated onto a monolayer of a cell culture
which is then observed for a toxin B-induced cytopathic effect
(rounding of the cells). The cytopathic effect is evaluated at 24 and
48 hours. Cell lines commonly used for CCNA include Vero cells,
HeLa cells, human foreskin ﬁbroblast cells and Hep-2 cells.
Neutralization of the cytopathic effect is necessary to determine
the speciﬁcity of this effect and can be done by using Clostridium
sordelli antitoxin or C. difﬁcile antitoxin [3]. This reference test
takes 1 to 2 days to perform and requires cell culture and labo-
ratory expertise, so it is not routinely used in most diagnostic
laboratories.
TC demonstrates the presence of C. difﬁcile, which is able to
produce toxins in vitro. Stools are incubated anaerobically for at
least 48 hours on selective media. Many different culture media
exist for this purpose, all aiming to enhance the recovery of
C. difﬁcilewhile inhibiting the overgrowth of other faecal ﬂora [4].
Pretreatment with alcohol shock [5] or heat shock can also be
used to decrease overgrowth of normal faecal ﬂora [4]. Also, broth
enrichment before plating onto a solid medium is sometimes used
(also called enriched culture) [4]. Furthermore, a chromogenic
medium (ChromID agar; bioMerieux) for the recovery of C. difﬁcile
has been developed which is designed to isolate and identify
C. difﬁcile within 24 hours. However, no consensus exists on
which culture medium and/or culture method is the most
appropriate to use. Colonies suspicious for C. difﬁcile can be
recognized by Gram staining, colony morphology, ‘horse manure’
odour, biochemical testing, gaseliquid chromatography, ultravi-
olet light ﬂuorescence, latex agglutination and matrix-assisted
desorption ionizationetime of ﬂight mass spectrometry [6]. Iso-
lates from positive cultures are either tested for in vitro toxin
production by the use of CCNA or toxin A/B enzyme immunoassay
(EIA) or tested for the presence of toxin A/B genes by NAAT.
As outlined above, both these reference tests detect different
things, and because of this theywill not necessarily agree with each
other in all samples. Results for each reference test will be analysed
separately.Index tests
Index tests are the tests whose performance is being evaluated
compared to the reference tests. The index tests we reviewed
comprise all commonly applied and commercially available labo-
ratory tests for diagnosing CDI other than the reference tests. These
include EIAs that detect glutamate dehydrogenase (GDH), EIAs that
detect toxins A and B and NAAT.
GDH EIAs detect glutamate dehydrogenase, an enzyme that is
produced by both toxigenic and nontoxigenic strains of C. difﬁcile.
GDH EIAs are available in well-type format (results are displayed as
a colour change which can be detected visually or photo-
spectrometically) ormembrane-type format (results can be visually
read from a membrane).
Toxin A/B EIAs detect toxins A and B and are also available in
well-type or membrane-type format. Most EIAs detecting only
toxin A have been replaced by EIAs detecting both toxins A and B, as
strains that only produce toxin B and not toxin A are reported.
Several membrane-type tests that include both an EIA detecting
GDH and an EIA detecting toxins A and B are also available (C. diff
Quik Chek Complete, Techlab, Combo C. difﬁcile; Theradiag).
NAATs include assays that use PCR, helicase-dependent
ampliﬁcation and loop-mediated isothermal ampliﬁcation. Most
assays detect conserved regions within the gene for toxin B (tcdB),
but assays that detect a highly conserved sequence of the toxin A
gene (tcdA) have also been developed (Illumigene, Meridian,
Bioscience and Amplivue, Quidel) [7,8]. NAATs that not only detect
tcdB but also the binary toxin genes (cdt) and the deletion at
nucleotide 117 on tcdC are also available (Verigene C. difﬁcile test,
Nanosphere and Xpert, Cepheid) and offer the potential advantage
of detecting PCR ribotype 027, although highly related PCR ribo-
types may also be detected by these tests (without distinguishing
them from PCR ribotype 027) [9]. NAATs that detect multiple
targets at the same time, including C. difﬁcile toxin genes, are also
available (Seeplex Diarrhea ACE detection, Seegene, xTAG
Gastrointestinal Pathogen Panel, Luminex, FilmArray Gastroin-
testinal Panel, BioFire Diagnostics).
Test performance
The numbers of truly positive, falsely positive, falsely negative
and truly negative index test results are generally displayed in a
2 2 table (Table 1). Test performance can be derived from this 2 2
table. The sensitivity of a test is deﬁned as the probability that the
index test result will be positive in a person with disease (a/aþ c).
The speciﬁcity of a test is deﬁned as the probability that the index
test result will be negative in a personwithout disease (d/bþ d). The
positive predictive value (PPV) of a test is the probability that a
person has the disease, given the positive test result (a/aþ b). The
negative predictive value (NPV) of a test is the probability that a
person is free of disease, given the negative test result (d/cþ d). PPV
and NPV are dependent on disease prevalence in the tested popu-
lation (http://training-old.cochrane.org/sites/training-old.cochrane.
org/ﬁles/uploads/DTA/1.3_Introduction_to_test_accuracy/story.
html).
Eligibility criteria
Studies eligible for inclusion had to: (1) describe original
research, (2) compare an index test (one commercially available in
M.J.T. Crobach et al. / Clinical Microbiology and Infection 22 (2016) S63eS81 S65Europe) with a reference test (CCNA or TC), (3) perform the tests on
C. difﬁcile-negative and -positive clinical human stool samples and
(4) provide sufﬁcient information to recalculate sensitivity and
speciﬁcity and their conﬁdence intervals. Culture without deter-
mining the toxigenic status was accepted as a reference test if only
assays detecting GDH were evaluated.
Studies were excluded if: (1) the reference test was not per-
formed on all samples but only on positive, negative or discordant
samples (to exclude partial veriﬁcation bias), (2) not all samples
were tested by the same reference test, (3) the reference method
was a composite of more than one test, (4) the reference method
included clinical data for its interpretation, (5) the index test was
partly used as reference method, (6) the index test did not follow
manufacturers' instructions for testing or sample collection, (7) for
CCNA, samples were not stored correctly before testing (refriger-
ated or frozen at 20C and thawed only once) or neutralization to
determine the speciﬁcity of the cytopathic effect was not executed
and (8) only selected samples were included.
Selection process
Study eligibility was assessed in a two-step selection process by
two independent investigators (MC, ET). Inconsistencies were
resolved by consensus and by consultation of a third and fourth
investigator (EK, TP).
Outcome measures, data extraction and quality assessment
The principal measures of outcome were the sensitivity and
speciﬁcity of different index tests compared to one of the 2 refer-
ence tests. Toxin A/B EIAs, GDH EIAs and NAATs were compared to
CCNA and TC. GDH EIAs were additionally compared to culture.
From each study we extracted the number of true-positive, false-
positive, false-negative and true-negative ﬁndings to be able to
calculate the sensitivity and speciﬁcity of the index test evaluated
in that study. Data were extracted by two independent in-
vestigators (MC, ET) using a data extraction form (Supplementary
Material 2). Additional data that were extracted included year of
publication, storage conditions of the samples, information about
the study population and information about the execution of the
index test and reference test.
The quality of the studies was assessed by the same two inde-
pendent investigators using a quality assessment tool. This quality
assessment tool (Supplementary Material 3) consisted of items
from the Quality Assessment for Studies of Diagnostic Accuracy
(QUADAS) tool [10], supplemented with items concerning the
appropriate handling of specimens and appropriate execution of
reference tests.
Statistical analysis
For all index tests in all studies, the sensitivity and speciﬁcity
and their respective conﬁdence intervals were calculated from theTable 2
Scoring system for grading quality of evidence and strength of recommendations
Quality of evidence
High quality Evidence from at least one properly desig
and direct comparison of all test results w
Moderate quality Evidence from: (1) at least one cross-sec
results with an appropriate reference sta
Low quality Evidence from opinions of respected auth
or reports of expert committees.
Strength of recommendation
Strong recommendation for use Desirable effects clearly outweigh undesi
Weak recommendation for use Desirable and undesirable effects are clos
Weak recommendation against use Desirable and undesirable effects are clos
Strong recommendation against use Undesirable effects clearly outweigh desi
Good practice statement Desirable effects clearly outweigh undesinumber of true-positive, false-positive, false-negative and true-
negative ﬁndings supplied in these studies. Wherever possible,
the results after initial testing (instead of results after retesting of
indeterminate results) were used to calculate the sensitivity and
speciﬁcity. Random effects logistic regression was used to pool the
mean sensitivities and speciﬁcities for the different index tests and
the different types of index tests. In case of fewer than four studies,
a ﬁxed effect model was used. NPVs and PPVs were calculated using
a hypothetical prevalence of CDI of 5, 10, 20 and 50% in the tested
population. We used Stata 12.0 software (StataCorp) for all statis-
tical analyses.
Guidelines and additional studies
An electronic search was performed on topics concerning lab-
oratory diagnosis of CDI not included in our meta-analysis (e.g.
repeated testing, sample selection). Published guidelines on CDI
testing were also studied. These included guidelines from the So-
ciety for Healthcare Epidemiology of America/Infectious Diseases
Society of America (published in 2010) [11], guidelines from the
Australasian Society for Infectious Diseases (published in 2011)
[12], guidelines from the American College of Gastroenterology
(published in 2013) [13], guidelines from the American Academy of
Pediatrics (published in 2013) [14] and guidelines from the UK
National Health Service (update published in 2012) [15].
Formulation of recommendations
The guideline was developed according to the Appraisal of
Guidelines for Research and Evaluation (AGREE II) instrument [16].
Findings of the literature review and meta-analysis results were
discussed with the members of the executive committee, and rec-
ommendations were formulated. We slightly modiﬁed the GRADE
system to grade the strength of the recommendations and the
quality of evidence [17] (Table 2). A good practice statement could
be made instead of a formal graded recommendation for domains
where this was deemed appropriate [18]. The drafting group (con-
sisting of experts in the ﬁeld) and a patients' representative were
invited to comment on the recommendations, and results from
these discussions were incorporated in the ﬁnal recommendations.
Results
Literature search and selection process
A total of 795 unique citations were identiﬁed by our current
search. On the basis of title and abstract, 693 articles were excluded,
leaving 102 full-text articles for detailed assessment. In total, 61
studies were excluded after detailed assessment. Reasons for
exclusion were (some studies had more than one reason forned cross-sectional or cohort study in patients with diagnostic uncertainty
ith an appropriate reference standard.
tional or cohort study in selected patients and/or no or partial comparison of test
ndard, (2) caseecontrol studies.
orities, based on clinical experience, descriptive case studies
rable effects.
ely balanced or recommendation is based on low-quality evidence.
ely balanced or recommendation is based on low-quality evidence.
rable effects.
rable effects, but no or only indirect evidence is/will become available.
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method (23 studies), no or an inadequate reference test was used
(16 studies), samples were selected inadequately (13 studies), not
enough information was provided (seven studies), the study did
not describe original research (ﬁve studies), no clinical human stool
samples were included (three studies), no commercial diagnostic
test was investigated (two studies) and stool samples were incor-
rectly collected in transport medium (one study).
From all 43 studies included in the previous meta-analysis [1],
28 were excluded. Twenty-four of these studies evaluated tests that
were no longer available (mainly EIAs detecting toxin A only). Two
other studies were excluded because they did not evaluate a
commercial test (both studies evaluated an in-house PCR), one
study was excluded because not all samples were tested by the
same reference test and one study was excluded because samples
were stored incorrectly for CCNA testing. A total of 56 studies (15
from the previous meta-analysis and 41 published since 2009)
were included in the meta-analysis [7,8,19e72]. A summary of the
selection process is shown in Fig. 1.
Study characteristics
Twenty-four different laboratory assays were evaluated: one
well-type EIA for GDH, three membrane-type EIAs for GDH, ﬁve43 studies from the previous 
review
102 studies selected for detailed 
assessment
795 potentially relevant studies 
identified by literature search 
(published since 2009)
56 studies included in current 
meta-analysis
41 studies included
15 studies included
Fig. 1. Summary of selection process. *Some studwell-type EIAs for toxins A and B, four membrane-type EIAs for
toxin A and B and 11 NAATs (Table 3). In total, 133 comparisons
between index tests and reference tests were available, including
53 comparisons to CCNA, 69 comparisons to TC and 11 comparisons
to culture. Studies were published between 1996 and 2014. The
number of evaluated index tests per study ranged from one to ten,
and the number of included samples ranged from 60 to 12 369. The
CDI prevalence in the tested population ranged from 6 to 48%.
Table 4 lists the characteristics of included studies.
Quality assessment
None of the studies fulﬁlled all our quality assessment criteria,
mainly because required information was frequently missing
(Fig. 2, Supplementary Material 4). The process used to select
samples was adequately reported in 23 (41%) of 56 studies. A
minority of studies (6/56, 11%) reported that they did not exclude
formed samples from CDI testing. In around half of the studies,
conditions of storage for the samples before testing with the
index test were not (or were insufﬁciently) reported. Samples
tested by GDH EIA, toxin A/B EIA and NAAT were reported to be
stored according to manufacturer's instructions in 10 (46%) of 22,
14 (45%) of 31 and 15 (50%) of 30 studies, respectively. In the
remaining 12, 16 and 15 studies, respectively, storage conditions28 articles excluded:
24 test not available 
anymore
2 no commercial test
1 not all samples tested by 
same reference test
1 samples for CCNA were 
stored incorrectly 
693 studies excluded on the 
basis of title or abstract
61 articles excluded*:
23 not all samples tested by 
(same) reference test
16 no or incorrect reference test
13 incorrect sample selection
7 not enough information
5 no original research
3 no clinical human stool samples
2 no commercial diagnostic test
1 incorrect sample collection
ies had more than one reason for exclusion.
Table 3
Index tests included in meta-analysis
Assay type Test Manufacturer Target Method
(A) Well-type EIA GDH C. diff Chek-60 Techlab GDH Well-type EIA
(B) Membrane-type EIA GDH C. diff Quik Chek Techlab GDH Membrane-type EIA
ImmunoCard C. difﬁcile Meridian GDH Membrane-type EIA
Quik Chek CompleteeGDHa Techlab GDH Membrane-type EIA
(C) Well-type EIA toxins A/B Premier toxins A/B Meridian Toxins A and B Well-type EIA
Remel ProSpecT Oxoid Toxins A and B Well-type EIA
Ridascreen toxins A/B Biopharm Toxins A and B Well-type EIA
Clostridium difﬁcile Tox A/B II Techlab Toxins A and B Well-type EIA
Vidas CDAB bioMerieux Toxins A and B Automated EIA
(D) Membrane-type
EIA toxins A/B
ImmunoCard toxins A/B Meridian Toxins A and B Membrane-type EIA
Quik Chek CompleteeTox A/Ba Techlab Toxins A and B Membrane-type EIA
Tox A/B Quik Chek Techlab Toxins A and B Membrane-type EIA
Xpect Oxoid Toxins A and B Membrane-type EIA
(E) NAAT Advansure CD LG Life Sciences tcdA, tcdB RT-PCR
Amplivue Quidel tcdA Isothermal helicase-dependent
ampliﬁcation
BD GeneOhm Becton Dickinson tcdB RT-PCR
BD Max Cdiff Becton, Dickinson tcdB RT-PCR
GenomEra Abacus Diagnostica tcdB RT-PCR
Illumigene Meridian tcdA LAMP
Portrait Great Basin tcdB Isothermal helicase-dependent
ampliﬁcation
Prodesse ProGastro Cd Assay Hologic Gen-Probe tcdB RT-PCR
Seeplex Diarrhea ACE Detectionc Seegene tcdB RT-PCR
Verigene Nanosphere tcdA, tcdB, cdt,b tcdC deletion nt 117b PCR/nanoparticle-based microarray
Xpert C. difﬁcile Cepheid tcdB, cdt, tcdC deletion nt 117 RT-PCR
EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; LAMP, loop-mediated isothermal DNA ampliﬁcation; RT-PCR, real-time PCR.
a Part of an EIA that detects both toxins A/B and GDH.
b Only for epidemiologic purposes.
c Multiplex PCR system.
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structions. In 18 (72%) of 25 studies using CCNA as the reference
test, samples were stored according to our predeﬁned storage
requirements: samples were either refrigerated and tested
within 5 days (15 studies) [8,25,27,36,45e48,58e61,63,65,68]
or were frozen at 20C and thawed no more than once (three
studies) [44,66,67]. In the remaining seven studies (28%), storage
conditions for CCNA were not or incompletely described.
Storage conditions for samples tested by TC were reported in 23
(68%) of 34 studies, but no speciﬁc requirements for storage of
samples tested by TC were set. The execution of the reference
test was described in sufﬁcient detail in 44 (79%) of 56 studies. In
2 (8%) of 26 studies using CCNA as reference test, the
incubation period was only 24 hours [61,63]. In studies using TC
as reference test, ethanol shock was reported to be performed
in 18 of 35 studies [19,21,23,32,35,37,38,47,51e55,57,61,69e71],
and heat shock was performed in three of 35 studies [22,49,58].
Eight studies (23%) used an enrichment broth before plating
onto a solid agar [19,22e24,32,43,58,62]. Toxigenicity was
conﬁrmed by PCR (15/32, 47%) [21,23,29,33e35,37,51e57,70],
CCNA (9/32, 28%) [7,8,22,24,43,47,58,61,62], toxin EIA (7/32, 22%)
[19,30,32,38,40,69,71] or both PCR and CCNA (1/32, 3%) [26].
Blinding (index test interpreted without knowledge of reference
test or vice versa) was reported in 8 (14%) of 56 studies. Thirty-
one studies (55%) reported if any indeterminate results (i.e.
invalid, ‘no call’ or difﬁcult-to-interpret results) were found.
Indeterminate results actually occurred in 28 studies and were
reported for one membrane-type GDH EIA (ImmunoCard
C. difﬁcile), three membrane-type toxin A/B EIAs (Tox A/B Quik
Chek, ImmunoCard Tox A/B, Xpect), one automated EIA (Vidas)
and nine NAATs. The amount of indeterminate results ranged
from 0.3 to 6.8% of tested samples. Repeat testing of samples
after an initial indeterminate result was done in 24 (86%) of these
28 studies. Of these, 22 presented results only after repeat testing
[7,8,20e22,24,29,30,34,35,37,38,43,46,47,54,58,59,62,65,69,70],and two presented results of both initial and repeat testing
[27,63].
Test performances
Sensitivity and speciﬁcity of the index tests were calculated on
the basis of the numbers provided in the articles. Discrepancies
between calculated sensitivity or speciﬁcity and published data
were found in two articles; the correct datawere provided by both
authors upon request [38,39]. In Table 5, sensitivity and speciﬁcity
of index tests are compared to CCNA. Reported estimates of
sensitivity ranged from 0.80 to 1.00 for GDH EIAs, from 0.44 to
0.99 for toxin A/B EIAs and from 0.83 to 1.00 for NAATs. Reported
estimates of speciﬁcity ranged from 0.82 to 0.95 for GDH EIAs,
from 0.87 to 1.00 for toxin A/B EIAs and from 0.87 to 0.98 for
NAATs. Table 6 lists sensitivity and speciﬁcity compared to TC.
Sensitivities ranged from 0.83 to 1.00, 0.29 to 0.86 and 0.77 to 1.0
for GDH EIAs, toxin A/B EIAs and NAATs, respectively. Speciﬁcities
ranged from 0.88 to 1.00, 0.91 to 1.00 and 0.83 to 1.00, respec-
tively. In Table 7, sensitivity and speciﬁcity of GDH EIAs are
compared to culture. Sensitivities ranged from 0.71 to 1.00, and
speciﬁcities ranged from 0.67 to 1.00. In Table 8, estimates of
pooled sensitivity and pooled speciﬁcity for the different cate-
gories of index tests are shown. The estimated pooled sensitivities
and speciﬁcities compared to CCNA were used to compute PPVs
and NPVs of the categories of index tests at different hypothetical
CDI prevalences (Table 9, Supplementary Material 5). At a CDI
prevalence of 5%, PPVs ranged from 34 to 81%, and NPVs ranged
from 99 to 100%. At a CDI prevalence of 50%, PPVs ranged from 91
to 99%, while NPVs ranged from 83 to 98%.
Discussion
In the present meta-analysis, we evaluated the diagnostic ac-
curacy of various commercial laboratory assays for diagnosing CDI.
Table 4
Characteristics of included studies
Study Year Country Reference test Index test Total no. samples Study population Consistency of
stool samples
Prevalence CDI
(CCNA)
Prevalence CDI
(TC)
Barkin [19] 2012 USA TC Premier toxins A/B,
ImmunoCard C. difﬁcile,
Illumigene
272 Adult inpatients of large community teaching
hospital with diarrhoea, risk factors for CDI and
for whom CDI test was requested by their
physician
Unformed 13.1
Berg, van den [66] 2005 Netherlands CCNA ImmunoCard toxins A/B 367 Unformed stools of adults with speciﬁc request
for CDI testing or hospitalized >72 hours that
were submitted to laboratories of three
university hospitals
Unformed 6.3
Berg, van den [67] 2007 Netherlands CCNA Premier toxins A/B 540 Unformed stools of patients suspected of having
CDI or hospitalized >72 hours in four university
medical centres
Unformed 5.7
Berry [20] 2014 UK CCNA Xpert 1034 Inpatients in two acute-care hospitals aged
>15 years with suspected CDI for whom CDI
testing was requested by treating physician
Unformed 6.0
Boer, de [25] 2010 Netherlands CCNA Xpect 161 Clinical stool specimens from patients for
whom request for CDI testing was issued,
prospectively collected at laboratory for
infectious diseases
Unclear 9.9
Bruins [21] 2012 Netherlands TC ImmunoCard toxins A/B,
Quik Chek Complete,
Premier toxins A/B,
Illumigene
986 Hospitalized and nonhospitalized patients with
diarrhoea who had stool sample sent to
laboratory of major hospital, preferably from
those patients known to have CDI-associated
symptoms or risk factors
Unformed 7.4
Buchan [22] 2012 USA TC Portrait, GeneXpert,
GeneOhm, Illumigene
540/275/169/96 Stool specimens from patients >2 years old
suspected of having CDI collected at four
institutions
Unformed 22.5
Calderaro [23] 2013 Italy TC Illumigene, Quik Chek
Complete
306 Patients attending university hospital with
suspicion of CDI
Unclear 19.6
Carroll [24] 2013 USA TC Verigene 1875 Leftover stool samples submitted speciﬁcally for
CDI testing according to institution's routine
practice to ﬁve geographically diverse clinical
microbiology laboratories
Formed and
unformed
8.4 (direct),
14.7 (enriched)
Eastwood [27] 2009 UK CCNA Premier toxins A/B, Xpect,
Tox A/B Quik Chek,
Ridascreen toxins A/B, Tox
A/B II, ProSpecT, VIDAS
CDAB, ImmunoCard toxins
A/B, C. diff Chek-60, BD
GeneOhm
488 Stool specimens submitted for CCNA testing at
laboratory of teaching hospital; ten samples
were randomly chosen each day
Unformed 18.1
M
.J.T.Crobach
et
al./
Clinical
M
icrobiology
and
Infection
22
(2016)
S63
e
S81
S68
Eckert [8] 2014 France CCNA, TC Amplivue, C. diff Quik Chek 308 Inpatients in four university-afﬁliated hospitals
>2 years old with suspected CDI for whom CDI
testing was requested by treating physician or if
diarrhoea occurred after day 3 of hospitalization
Unformed 7.5 11.7
Fenner [28] 2008 Switzerland Culture C. diff Chek-60 1468 Stools of adults patients suspected of having CDI
at university hospital
Unclear 12.7 culture
positive
Hart [29] 2014 Australia Culture, TC Illumigene, BD GeneOhm,
Quik Chek Complete
150 Stools of children collected at laboratory of
paediatric hospital fulﬁlling criteria for CDI
testing in this hospitala
Formed (4%)
and unformed
(96%)
30.0
Hirvonen [30] 2013 Finland TC GenomEra 310 Stool specimens from inpatients (7e95 years
old), collected prospectively according to
routine hospital practice for antibiotic-
associated diarrhoea at large teaching hospital
Unformed 24.9
Huang [31] 2009 Sweden CCNA Xpert 220 Consecutive stool specimens from patients
>2 years old who were symptomatic and had
request for CDI testing at university hospital
Unformed 10.5
Jacobs [32] 1996 Israel Culture, TC ImmunoCard C. difﬁcile 258 Stool samples from patients who developed
diarrhoea during hospitalization in community
teaching hospital and control samples from 24
patients without diarrhoea
Formed and
unformed
7.0
Jong [26] 2012 Netherlands TC ImmunoCard toxins A/B,
VIDAS CDAB
150 Hospitalized adult patients in tertiary teaching
hospital who had stool specimens submitted for
CDI testing
Unclear 9.7
Kawada [33] 2011 Japan Culture, TC Quik Chek Complete,
ImmunoCard C. difﬁcile, Tox
A/B Quik Chek
60 Patients hospitalized at geriatric hospital and
diagnosed as having antibiotic-associated
diarrhoea
Unformed 46.7
Kim [35] 2014 Korea TC Quik Chek Complete, VIDAS
CDAB
608 Suspected CDI patients in tertiary-care teaching
hospital
Unformed 9.0
Kim [34] 2012 Korea TC AdvanSure, VIDAS CDAB 127 Diarrhoeal stool specimens submitted to
hospital laboratory for C. difﬁcile culture
Unformed 8.8
Lalande [7] 2011 France TC Illumigene 472 Consecutive stools from patients suspected of
having CDI
Unformed 10.4
Larson [36] 2010 USA CCNA C. diff Quik Chek 699 Stool samples submitted for CDI testing from
adult patients at university hospital
Unformed 6.7
Le Guern [37] 2012 France TC BDMax Cdiff, BD GeneOhm,
Tox A/B Quik Chek
360 Diarrhoeal stool specimens collected from
inpatients at university hospital
Unformed 12.2
(continued on next page)
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Table 4 (continued )
Study Year Country Reference test Index test Total no. samples Study population Consistency of
stool samples
Prevalence CDI
(CCNA)
Prevalence CDI
(TC)
Leitner [38] 2013 Austria TC BD Max Cdiff, Premier
toxins A/B
180 Stool specimens from adults and children with
speciﬁed request for CDI testing at medical
university
Unformed 16.7
Massey [39] 2003 Candada CCNA Tox A/B II 557 Stool samples of adult hospitalized patients
suspected of having CDI at large teaching
hospital
Unformed 25.7
Mattner [40] 2012 Germany TC Ridascreen 254 All liquid stool samples sent to university
microbiology laboratory
Unformed 16.4
Musher [41] 2007 USA CCNA Premier toxins A/B,
ImmunoCard toxins A/B,
Tox A/B II, ProSpecT
446/131 Consecutive stool samples submitted to
laboratory of medical centre for CDI testing
Unclear 17.0/41.2
Noren [42] 2011 Sweden CCNA Illumigene 272 Consecutive stool specimens from adults and
children submitted for CDI testing from
hospitals and communities
Unclear 13.2
Novak-Weekley
[43]
2010 USA TC Xpert, Premier A/B 432 Leftover stool samples from patients >2 years
old with suspected CDI for whom toxin enzyme
immunoassays were ordered according to
institution's standard practices at regional
reference laboratories serving hospitals and
associated medical clinics
Unformed 16.8
O'Connor [44] 2001 Ireland CCNA Tox A/B II, Premier toxins A/
B
200 Consecutive stools of adult patients suspected
of having CDI submitted to laboratories of
university hospitals
Formed and
unformed
30.5
Ota [45] 2012 USA CCNA C. diff Quik Chek Complete,
Premier toxins A/B,
Illumigene
141 Consecutive stool specimens prospectively
collected at children's hospital from patients 1
e18 years of age and submitted for CDI testing
Unformed 18.4
Pancholi [46] 2012 USA CCNA Illumigene, Xpert 200 Consecutive and prospectively collected stools
from adult patients submitted to university
medical centre laboratory for routine CDI
testing
Unformed 11.6
Planche [47] 2013 UK CCNA, TC Xpert, C. diff Chek-60,
Premier toxins A/B, Tox A/B
II
8827/12 365/
9192/12 369
Faecal samples from hospital and community
patients submitted for routine CDI testing
according to routine protocolb submitted to four
hospital diagnostic laboratories serving major
teaching hospitals and their communities
Unformed 5.9 8.4
Qutub [48] 2011 Saudi Arabia CCNA C. diff Chek-60, Tox A/B II 150 Stool samples from consecutive inpatients with
suspected CDI
Unformed 34.7
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Reller [49] 2007 USA Culture C. diff Chek-60 439 Stool samples from hospitalized adults and
children suspected of having CDI
Unclear 36.7 culture
positive
Reller [50] 2010 USA CCNA C. diff Chek-60, C. diff Quik
Chek, Tox A/B Quik Chek
600 Sequential weekday stool samples submitted to
university hospital microbiology laboratory for
CDI testing
Unformed 7.7
Shin [52] 2009 Korea TC Vidas CDAB 1596 Stool samples from patients admitted to tertiary
teaching hospital with clinical signs compatible
with CDI
19.6
Shin [51] 2009 Korea TC Vidas CDAB 555 Patients >2 years old with suspected CDI from
two hospitals
Formed (51%)
and unformed
20.3
Shin [53] 2012 Korea TC Seegene, BD GeneOhm 243 Fresh stool specimens from patients with
clinical signs compatible with CDI who were
hospitalized in 3 teaching hospitals
Unclear 28.8
Shin [54] 2012 Korea TC Xpert/epi, Vidas CDAB 253 Consecutive stool specimens from suspected
CDI patients in tertiary hospital
Unformed 18.4
Sloan [55] 2008 USA TC Premier toxins A/B, Xpect,
ImmunoCard A/B
200 Stools of patients suspected of having CDI
submitted to clinical microbiology laboratory of
large tertiary-care teaching hospital
Unformed 22.0
Snell [56] 2004 Canada Culture, TC C. diff Chek-60, Tox A/B II 497 Stools of inpatients suspected of having CDI at
large teaching hospital
Unformed 10.5
Soh [57] 2014 Korea TC AdvanSure CD, Illumigene 203 Stool samples collected at tertiary university
teaching hospital
Unformed 12.8
Stamper [59] 2009 USA CCNA BD GeneOhm 401 Symptomatic adult patients who had stool
sample submitted for routine CDI testing in
tertiary-care university medical centre
Unformed 11.0
Stamper [58] 2009 USA CCNA, TC ProGastro CD 280 Stool samples submitted for routine CDI testing
from symptomatic patients >2 years old at
tertiary-care university medical institution
Unformed 11.0 15.7
Staneck [60] 1996 USA CCNA ImmunoCard C. difﬁcile 906 Stool samples submitted to three hospital
microbiology laboratories
Unclear 14.1
Swindells [61] 2010 UK Culture, CCNA,
TC
C. diff Quik Chek Complete,
Vidas CDAB, Xpert,
GeneOhm
150 Consecutive stool specimens from inpatients
>65 years old who developed diarrhoea at least
48 hours after admission
Unformed 10.0 12.0
Tenover [62] 2010 USA/Canada TC Xpert 2296 Leftover stool specimens from patients >2 years
old from seven health care organizations (six
USA, one Canada) for whom CDI testing was
ordered according to institution's practices
Unformed 10.8 (direct),
14.7 (enriched)
(continued on next page)
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Table 4 (continued )
Study Year Country Reference test Index test Total no. samples Study population Consistency of
stool samples
Prevalence CDI
(CCNA)
Prevalence CDI
(TC)
Terhes [63] 2009 Hungary CCNA BD GeneOhm 600 Inpatients and outpatients at local university
hospital who had diarrhoeal stool sample sent
to laboratory for CDI testing
Unformed 6.4
Ticehurst [64] 2006 USA CCNA C. diff Chek-60 266 Stools of patients suspected of having CDI
submitted to laboratories of two acute-care
hospitals
Unclear 9.0
Turgeon [65] 2003 USA CCNA ImmunoCard C. difﬁcile 1003 Consecutive stools of adults and children
suspected of having CDI at ﬁve major hospitals
Unformed and
formed
10.1
Vanpoucke [68] 2001 Belgium CCNA Ridascreen 156 Stool specimens submitted to laboratory of
university hospital with request for CDI testing
Unformed 31.8
Viala [69] 2012 France TC BD GeneOhm, Xpert,
Illumigene
94 Fresh stool specimens from symptomatic
patients collected at university hospital, 45 TC
positive and 49 TC negative were selected
Unformed 47.8
Walkty [70] 2013 Canada TC Illumigene, C. diff Quik Chek 428 All diarrhoeal stool specimens from patients
>1 year old submitted for CDI testing to three
microbiological laboratories serving major
hospitals and surrounding communities
Unformed 14.7
Wren [71] 2009 UK Culture, TC C. diff Quik Chek, Tox A/B
Quik Chek
1007 Stool samples submitted for CDI testing from
patients who developed diarrhoea after being
admitted to major university hospitals
Unformed 8.6
Zheng [72] 2004 USA Culture C. diff Chek-60 992 Stool samples submitted for routine CDI testing
because of antibiotic-associated diarrhoea
collected from hospital laboratories and
supplied to TechLab, a large medical centre and
reference laboratory
Unclear 13.8
CCNA, cell cytotoxicity neutralization assay; CDI, Clostridium difﬁcile infection; TC, toxigenic culture.
a Criteria were: oncology/haematology patient, speciﬁc request for CDI testing by treating physician, history of diarrhoea developed while receiving antibiotics, or pseudomembranous colitis.
b Criteria were: all unformed faecal samples not clearly attributable to an underlying disease, or treatment from all hospital patients >2 years and from individuals in the community >65 years irrespective of C. difﬁcile or other
testing requests.
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Fig. 2. Quality assessment of included studies.
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EIAs and NAATsweremore sensitive tests. Althoughmany toxin A/B
EIAs belong to the least sensitive tests, the sensitivity of this cate-
gory of assays is not as low as reported earlier [1]. This is because
only currently available tests were included in the present analysis,
and the newer generation of toxin A/B EIAs turns out to be more
sensitive than the earlier toxin A EIAs.
We compared all categories of the index tests (GDH EIAs, toxin
A/B EIAs and NAATs) to both of the reference tests, CCNA and TC.
However, not only are the targets of these three categories of index
tests somewhat different, but also the targets of the two reference
tests differ: CCNA detects in vivo toxin production, while TC detects
the presence of a toxigenic C. difﬁcile strain.
This explains why sensitivities and speciﬁcities were different
for each reference test that was used as a comparator. For example,
toxin A/B EIAs were less sensitive compared to TC instead of CCNA:
toxin EIAs will not (like the TC) detect all samples containing
toxigenic C. difﬁcile strains but only (some of) those with free toxin
present. It also explains why NAATs were less speciﬁc compared to
CCNA instead of TC: NAATs are not able (like CCNA) to discern
samples with in vivo toxin production from samples with in vitro
toxin production.
We included both CCNA and TC as reference tests, as there has
always been debate which of these tests best deﬁnes CDI cases.
Recently a large study reported that CCNA positivity (i.e. demon-
stration of free toxin) but not TC positivity (i.e. demonstration of
toxin-producing capacity) correlated with clinical outcome.
Therefore, at least all samples with a positive CCNA can be
considered to represent true CDI cases [47]. However, samples with
a positive TC but negative CCNA are difﬁcult to interpret. These
samples could either belong to C. difﬁcile carriers (harbouring a
toxigenic C. difﬁcile strain not producing detectable toxins at that
moment) or to patients with CDI with toxin levels below the
threshold of detection.To guarantee a certain level of uniformity and quality, only
studies that met our eligibility criteria were included in the meta-
analysis. Still, studies differed from one another in many aspects.
For CCNA, diverse dilutions of faecal ﬁltrate and diverse cell lines
were used. For TC, diverse culture media and diverse methods to
demonstrate toxigenicity were applied. Also, none of the studies
satisﬁed all our quality assessment criteria. Notwithstanding these
differences, all included studies met the minimaldquite
strictdrequirements we set. We therefore think that it is justiﬁable
that we calculated summary estimates of sensitivity and speciﬁcity,
especially because we intended to provide a general overview of
test performances of different categories of laboratory assays
instead of pointing out one ‘best’ assay. It is, however, important to
realize that test performances of individual assays may have been
inﬂuenced by the design of included studies analysing these tests.
Besides, test characteristics presented here should not be consid-
ered unchanging over time and should not be considered ﬁxed
characteristics. This is because procedures of commercial assays are
sometimes revised to enhance test performance, and also because
assays may perform differently among different populations (e.g.
high- vs. low-risk patients). Also, in all categories, new assays were
marketed. The introduction of newer toxin A/B EIAs leading to a
better sensitivity of this category of assays is a good example of the
latter.
On the basis of the review results, PPVs and NPVs were calcu-
lated at different hypothetical prevalences of CDI in the tested
population. The prevalence of CDI can be seen as the pretest
probability of having CDI and would typically be around 5e10% in
an endemic setting [73]. At a CDI prevalence of 5%, even the most
speciﬁc tests (toxin A/B EIAs) would have PPVs of only 69e81%. On
the contrary, NPVs would be very high for all index tests. If the
prevalence of CDI would rise to 50% among the tested patients, the
PPV would consequently raise to 98.8% for the most speciﬁc test,
but the NPV would drop to 82.5% for the least sensitive tests. Both
Table 5
Sensitivity and speciﬁcity of index tests compared to CCNA
Type Index test Study Sensitivity (95% CI) Speciﬁcity (95% CI)
(A) Well-type EIA GDH C. diff Chek-60 Eastwood [27] 0.90 (0.82e0.95) 0.93 (0.90e0.95)
C. diff Chek-60 Planche [47] 0.96 (0.95e0.98) 0.92 (0.92e0.93)
C. diff Chek-60 Qutub [48] 0.94 (0.84e0.99) 0.88 (0.80e0.94)
C. diff Chek-60 Reller [50] 0.91 (0.79e0.98) 0.90 (0.87e0.92)
C. diff Chek-60 Ticehurst [64] 0.96 (0.79e1.00) 0.90 (0.86e0.94)
(B) Membrane-type EIA GDH C. diff Quik Chek Eckert [8] 1.00 (0.85e1.00) 0.92 (0.88e0.94)
C. diff Quik Chek Larson [36] 1.00 (0.92e1.00) 0.90 (0.87e0.92)
C. diff Quik Chek Reller [50] 1.00 (0.92e1.00) 0.83 (0.79e0.86)
ImmunoCard C. difﬁcile Staneck [60] 0.84 (0.77e0.90) 0.92 (0.90e0.94)
ImmunoCard C. difﬁcile Turgeon [65] 0.80 (0.71e0.87) 0.92 (0.91e0.94)
Quik Chek Complete-GDH Ota [45] 0.81 (0.61e0.93) 0.82 (0.73e0.88)
Quik Chek Complete-GDH Swindells [61] 1.00 (0.78e1.00) 0.95 (0.90e0.98)
(C) Well-type EIA toxins A/B Clostridium difﬁcile Tox A/B II Eastwood [27] 0.91 (0.84e0.95) 0.96 (0.93e0.97)
Clostridium difﬁcile Tox A/B II Massey [39] 0.75 (0.67e0.82) 0.98 (0.96e0.99)
Clostridium difﬁcile Tox A/B II Musher [41] 0.96 (0.87e1.00) 0.87 (0.77e0.94)
Clostridium difﬁcile Tox A/B II O'Connor [44] 0.80 (0.68e0.89) 0.99 (0.96e1.00)
Clostridium difﬁcile Tox A/B II Planche [47] 0.83 (0.80e0.86) 0.99 (0.99e0.99)
Clostridium difﬁcile Tox A/B II Qutub [48] 0.73 (0.59e0.84) 1.00 (0.96e1.00)
Premier toxins A/B Berg, van den 2007 [67] 0.97 (0.83e1.00) 0.94 (0.92e0.96)
Premier toxins A/B Eastwood [27] 0.92 (0.85e0.96) 0.97 (0.95e0.98)
Premier toxins A/B Musher [41] 0.99 (0.93e1.00) 0.97 (0.95e0.99)
Premier toxins A/B O'Connor [44] 0.82 (0.70e0.91) 0.99 (0.96e1.00)
Premier toxins A/B Ota [45] 0.58 (0.37e0.77) 1.00 (0.97e1.00)
Premier toxins A/B Planche [47] 0.67 (0.63e0.71) 0.99 (0.99e0.99)
Remel ProSpecT Eastwood [27] 0.90 (0.83e0.95) 0.93 (0.90e0.95)
Remel ProSpecT Musher [41] 0.91 (0.80e0.97) 0.97 (0.91e1.00)
Ridascreen toxins A/B Eastwood [27] 0.67 (0.57e0.75) 0.95 (0.93e0.97)
Ridascreen toxins A/B Vanpoucke [68] 0.57 (0.43e0.70) 0.97 (0.92e0.99)
(D) Membrane-type EIA toxins A/B ImmunoCard toxins A/B Berg, van den (2005) [66] 0.91 (0.72e0.99) 0.97 (0.95e0.99)
ImmunoCard toxins A/B Eastwood [27] 0.85 (0.76e0.91) 0.99 (0.98e1.00)
ImmunoCard toxins A/B Musher [41] 0.96 (0.89e0.99) 0.99 (0.97e1.00)
Quik Chek Complete-Tox A/B Ota [45] 0.50 (0.30e0.70) 1.00 (0.97e1.00)
Quik Chek Complete-Tox A/B Swindells [61] 0.73 (0.45e0.92) 1.00 (0.97e1.00)
Tox A/B Quik Chek Eastwood [27] 0.84 (0.76e0.91) 0.99 (0.98e1.00)
Tox A/B Quik Chek Reller [50] 0.61 (0.45e0.75) 0.99 (0.98e1.00)
Xpect Boer, de [25] 0.44 (0.20e0.70) 1.00 (0.97e1.00)
Xpect Eastwood [27] 0.83 (0.74e0.90) 0.99 (0.98e1.00)
(E) Automated EIA toxins A/B VIDAS CDAB Eastwood [27] 0.98 (0.93e1.00) 0.99 (0.98e1.00)
VIDAS CDAB Swindells [61] 0.53 (0.27e0.79) 1.00 (0.97e1.00)
(F) NAAT Amplivue Eckert [8] 0.96 (0.78e1.00) 0.95 (0.91e0.97)
BD GeneOhm Eastwood [27] 0.92 (0.85e0.97) 0.95 (0.93e0.97)
BD GeneOhm Stamper (2009e1) [59] 0.91 (0.78e0.97) 0.95 (0.92e0.97)
BD GeneOhm Swindells [61] 1.00 (0.78e1.00) 0.98 (0.94e1.00)
BD GeneOhm Terhes [63] 0.95 (0.82e0.99) 0.96 (0.94e0.98)
Illumigene Noren [42] 1.00 (0.90e1.00) 0.93 (0.89e0.96)
Illumigene Ota [45] 0.88 (0.70e0.98) 0.97 (0.93e0.99)
Illumigene Pancholi [46] 0.87 (0.66e0.97) 0.91 (0.86e0.95)
Prodesse ProGastro Cd assay Stamper (2009e2) [58] 0.83 (0.65e0.94) 0.96 (0.92e0.98)
Xpert C. difﬁcile Berry [20] 1.00 (0.94e1.00) 0.94 (0.92e0.95)
Xpert C. difﬁcile Huang [31] 0.96 (0.78e1.00) 0.87 (0.82e0.92)
Xpert C. difﬁcile Pancholi [46] 1.00 (0.85e1.00) 0.89 (0.83e0.93)
Xpert C. difﬁcile Planche [47] 0.98 (0.96e0.99) 0.93 (0.92e0.94)
Xpert C. difﬁcile Swindells [61] 1.00 (0.78e1.00) 0.97 (0.93e0.99)
CI, conﬁdence interval; CCNA, cell cytotoxicity neutralization assay; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test.
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many patients with false-positive results. These noninfected pa-
tients may receive unnecessary treatment for CDI, and unnecessary
isolation precautions may be taken. A low NPV will result in many
undetected cases, which may not only have implications for indi-
vidual patients but also for further transmission of C. difﬁcile. It is
therefore important to be aware not only of the sensitivity and
speciﬁcity of an assay but also of the CDI prevalence in the tested
population, as the predictive values and hence the clinical utility of
the assays depend on them.
The easiest way to diagnose CDI would be to use a single rapid
laboratory test that is able to reliably predict disease status. A rapid
CDI diagnosis is associated with more prompt CDI treatment and
less unnecessarily treated patients [74]. However, two problems
arise if the rapid assays are used as stand-alone test for diagnosingCDI. First, as described above, the PPVs of even the most speciﬁc
tests are inadequate at low disease prevalence. If toxin EIAs were to
be used in an endemic situation (CDI prevalence of 5% in the tested
population, PPV 81%), an unacceptably high percentage (19%) of
patients with a positive test result would not actually have CDI.
Second, as the targets identiﬁed by the index tests are (just like the
targets of the reference test) different from each other, a positive
index test does not necessarily indicate a real CDI case. Two of the
three categories of index test are not able to differentiate carriers
from CDI patients: both GDH EIAs and NAATs do not detect free
toxins. Using NAAT as a stand-alone test and relying on clinical
symptoms to discern patients with CDI from asymptomatic carriers
is not an optimal approach: patients colonized by a toxigenic
C. difﬁcile strain may very well develop diarrhoea due to other
causes, and no speciﬁc clinical symptoms exist to differentiate CDI
Table 6
Sensitivity and speciﬁcity of index tests compared to TC
Type Index test Study Sensitivity (95% CI) Speciﬁcity (95% CI)
(A) Well-type EIA GDH C. diff Chek-60 Planche [47] 0.94 (0.93e0.96) 0.94 (0.94e0.95)
(B) Membrane-type EIA GDH C. diff Quik Chek Eckert [8] 0.97 (0.85e1.00) 0.95 (0.92e0.97)
C. diff Quik Chek Walkty [70] 0.83 (0.71e0.91) 0.97 (0.95e0.98)
ImmunoCard C. difﬁcile Barkin [19] 1.00 (0.90e1.00) 1.00 (0.98e1.00)
ImmunoCard C. difﬁcile Jacobs [32] 0.60 (0.32e0.84) 0.76 (0.68e0.83)
Quik Chek CompletedGDH Bruins [21] 0.97 (0.90e1.00) 0.98 (0.96e0.98)
Quik Chek CompletedGDH Kawada [33] 1.00 (0.88e1.00) 0.88 (0.71e0.96)
Quik Chek CompletedGDH Swindells [61] 1.00 (0.81e1.00) 0.97 (0.92e0.99)
(C) Well-type EIA toxins A/B Clostridium difﬁcile Tox A/B II Planche [47] 0.58 (0.55e0.61) 0.99 (0.98e0.99)
Clostridium difﬁcile Tox A/B II Snell [56] 0.85 (0.72e0.93) 0.98 (0.96e0.99)
Premier toxins A/B Barkin [19] 0.86 (0.71e0.95) 0.91 (0.86e0.94)
Premier toxins A/B Bruins [21] 0.41 (0.30e0.53) 0.99 (0.98e0.99)
Premier toxins A/B Leitner [38] 0.40 (0.21e0.61) 1.00 (0.98e1.00)
Premier toxins A/B Novak-Weekley [43] 0.58 (0.46e0.70) 0.95 (0.92e0.97)
Premier toxins A/B Planche [47] 0.46 (0.42e0.49) 0.99 (0.99e0.99)
Premier toxins A/B Sloan [55] 0.48 (0.32e0.63) 0.98 (0.94e1.00)
Ridascreen toxins A/B Mattner [40] 0.52 (0.36e0.68) 0.98 (0.95e0.99)
(D) Membrane-type EIA toxins A/B ImmunoCard toxins A/B Bruins [21] 0.41 (0.30e0.53) 0.99 (0.98e1.00)
ImmunoCard toxins A/B de Jong [26] 0.47 (0.23e0.72) 0.99 (0.96e1.00)
ImmunoCard toxins A/B Sloan [55] 0.48 (0.32e0.63) 0.99 (0.95e1.00)
Quik Chek CompletedTox A/B Bruins [21] 0.55 (0.43e0.66) 1.00 (1.00e1.00)
Quik Chek CompletedTox A/B Calderaro [23] 0.68 (0.55e0.80) 0.89 (0.84e0.92)
Quik Chek CompletedTox A/B Hart [29] 0.29 (0.16e0.44) 1.00 (0.97e1.00)
Quik Chek CompletedTox A/B Kawada [33] 0.79 (0.59e0.92) 0.97 (0.84e1.00)
Quik Chek CompletedTox A/B Kim (2014) [35] 0.64 (0.50e0.76) 0.98 (0.96e0.99)
Quik Chek CompletedTox A/B Swindells [61] 0.61 (0.36e0.83) 1.00 (0.97e1.00)
Tox A/B Quik Chek Kawada [33] 0.71 (0.51e0.87) 0.94 (0.79e0.99)
Tox A/B Quik Chek Le Guern [37] 0.43 (0.28e0.59) 1.00 (0.98e1.00)
Tox A/B Quik Chek Wren [71] 0.40 (0.30e0.51) 1.00 (1.00e1.00)
Xpect Sloan [55] 0.48 (0.32e0.63) 0.84 (0.77e0.89)
(E) Automated EIA toxins A/B VIDAS CDAB Jong, de [26] 0.71 (0.42e0.92) 0.95 (0.90e0.98)
VIDAS CDAB Kim (2012) [34] 0.64 (0.31e0.89) 1.00 (0.97e1.00)
VIDAS CDAB Kim (2014) [35] 0.76 (0.61e0.87) 0.97 (0.96e0.99)
VIDAS CDAB Shin (2009e1) [52] 0.68 (0.62e0.73) 0.96 (0.95e0.97)
VIDAS CDAB Shin (2009e2) [51] 0.69 (0.59e0.78) 0.97 (0.94e0.98)
VIDAS CDAB Shin (2012e2) [54] 0.44 (0.30e0.60) 1.00 (0.98e1.00)
VIDAS CDAB Swindells [61] 0.44 (0.22e0.69) 1.00 (0.97e1.00)
(F) NAAT Advansure CD Kim (2012) [34] 1.00 (0.72e1.00) 0.98 (0.94e1.00)
Advansure CD Soh [57] 0.85 (0.65e0.96) 0.98 (0.95e1.00)
Amplivue Eckert [8] 0.86 (0.71e0.95) 0.98 (0.95e0.99)
BD GeneOhm Buchan [22] 0.97 (0.86e1.00) 0.98 (0.95e1.00)
BD GeneOhm Hart [29] 0.89 (0.76e0.96) 0.99 (0.95e1.00)
BD GeneOhm Le Guern [37] 0.95 (0.85e0.99) 1.00 (0.98e1.00)
BD GeneOhm Shin (2012e1) [53] 0.96 (0.88e0.99) 0.97 (0.93e0.99)
BD GeneOhm Swindells [61] 0.94 (0.73e1.00) 0.99 (0.96e1.00)
BD GeneOhm Viala [69] 0.96 (0.85e0.99) 0.98 (0.89e1.00)
BD Max Cdiff Le Guern [37] 0.98 (0.88e1.00) 1.00 (0.98e1.00)
BD Max Cdiff Leitner [38] 0.96 (0.80e1.00) 0.99 (0.96e1.00)
GenomEra Hirvonen [30] 1.00 (0.95e1.00) 0.99 (0.96e1.00)
Illumigene Barkin [19] 1.00 (0.90e1.00) 1.00 (0.98e1.00)
Illumigene Bruins [21] 0.93 (0.85e0.98) 1.00 (0.99e1.00)
Illumigene Buchan [22] 0.93 (0.68e1.00) 0.95 (0.88e0.99)
Illumigene Calderaro [23] 1.00 (0.94e1.00) 0.83 (0.78e0.87)
Illumigene Hart [29] 0.89 (0.76e0.96) 1.00 (0.97e1.00)
Illumigene Lalande [7] 0.92 (0.80e0.98) 0.99 (0.98e1.00)
Illumigene Soh [57] 0.92 (0.75e0.99) 0.99 (0.97e1.00)
Illumigene Viala [69] 0.87 (0.73e0.95) 1.00 (0.93e1.00)
Illumigene Walkty [70] 0.73 (0.60e0.83) 1.00 (0.98e1.00)
Portrait Buchan [22] 0.98 (0.94e1.00) 0.93 (0.90e0.95)
Prodesse ProGastro Cd assay Stamper (2009e2) [58] 0.77 (0.62e0.89) 0.99 (0.97e1.00)
Seeplex ACE Shin (2012e1) [53] 0.90 (0.80e0.96) 0.97 (0.93e0.99)
Verigene Caroll [24] 0.91 (0.87e0.94) 0.93 (0.91e0.94)
Xpert C. difﬁcile Buchan [22] 1.00 (0.94e1.00) 0.92 (0.87e0.95)
Xpert C. difﬁcile Novak-Weekley [43] 0.94 (0.86e0.98) 0.96 (0.94e0.98)
Xpert C. difﬁcile Planche [47] 0.95 (0.93e0.96) 0.96 (0.96e0.97)
Xpert C. difﬁcile Shin (2012e2) [54] 1.00 (0.93e1.00) 0.95 (0.91e0.98)
Xpert C. difﬁcile Swindells [61] 1.00 (0.81e1.00) 0.99 (0.96e1.00)
Xpert C. difﬁcile Tenover [62] 0.93 (0.90e0.96) 0.94 (0.93e0.95)
Xpert C. difﬁcile Viala [69] 0.98 (0.88e1.00) 0.98 (0.89e1.00)
CI, conﬁdence interval; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test; TC, toxigenic culture.
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Table 7
Sensitivity and speciﬁcity of index tests compared to culture
Type Index test Study Sensitivity (95% CI) Speciﬁcity (95% CI)
(A) Well-type EIA GDH C. diff Chek-60 Fenner [28] 0.93 (0.88e0.97) 0.97 (0.95e0.97)
C. diff Chek-60 Reller (2007) [49] 1.00 (0.98e1.00) 0.67 (0.61e0.72)
C. diff Chek-60 Snell [56] 0.94 (0.86e0.98) 0.98 (0.96e0.99)
C. diff Chek-60 Zheng [72] 0.71 (0.63e0.78) 0.88 (0.85e0.90)
(B) Membrane-type EIA GDH C. diff Quik Chek Wren [71] 0.95 (0.90e0.98) 0.99 (0.98e1.00)
Quik Chek CompletedGDH Bruins [21] 0.95 (0.89e0.99) 0.99 (0.98e0.99)
Quik Chek CompletedGDH Hart [29] 0.87 (0.75e0.95) 0.97 (0.91e0.99)
Quik Chek CompletedGDH Kawada [33] 1.00 (0.88e1.00) 0.93 (0.78e0.99)
Quik Chek CompletedGDH Swindells [61] 1.00 (0.82e1.00) 0.98 (0.93e1.00)
ImmunoCard C. difﬁcile Jacobs [32] 0.75 (0.59e0.87) 0.90 (0.83e0.95)
ImmunoCard C. difﬁcile Kawada [33] 0.80 (0.61e0.92) 1.00 (0.88e1.00)
CI, conﬁdence interval; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test.
Table 8
Pooled sensitivities and speciﬁcities of categories of tests
Type Test Compared to CCNA Compared to TC Compared to culture
No. of
studies
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
No. of
studies
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
No. of
studies
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
EIA GDH Total 12 0.94 (0.89e0.97) 0.90 (0.88e0.92) 8 0.96 (0.86e0.99) 0.96 (0.91e0.98) 11 0.94 (0.86e0.97) 0.96 (0.92e0.98)
Well type 5 0.94 (0.91e0.97) 0.92 (0.92e0.93) 1 0.94 (0.93e0.96) 0.94 (0.94e0.95) 4 0.89 (0.86e0.91) 0.91 (0.90e0.92)
Membrane
type
7 0.98 (0.78e1.00) 0.90 (0.87e0.93) 7 0.97 (0.84e1.00) 0.96 (0.90e0.99) 7 0.93 (0.84e0.97) 0.98 (0.95e0.99)
EIA
toxins A/B
Total 27 0.83 (0.76e0.88) 0.99 (0.98e0.99) 29 0.57 (0.51e0.63) 0.99 (0.98e0.99)
Well type 18 0.85 (0.77e0.91) 0.98 (0.96e0.99) 16 0.60 (0.52e0.68) 0.98 (0.97e0.99)
Membrane
type
9 0.79 (0.66e0.88) 0.99 (0.98e0.99) 13 0.53 (0.45e0.61) 0.99 (0.97e1.00)
NAAT 14 0.96 (0.93e0.98) 0.94 (0.93e0.95) 32 0.95 (0.92e0.97) 0.98 (0.97e0.99)
CI, conﬁdence interval; CCNA, cell cytotoxicity neutralization assay; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test; TC,
toxigenic culture.
Table 9
PPV and NPV for different categories of index tests at hypothetical CDI prevalences of 5, 10, 20 and 50%
Test type CDI prevalence 5% CDI prevalence 10% CDI prevalence 20% CDI prevalence 50%
PPV NPV PPV NPV PPV NPV PPV NPV
Well-type EIA GDH 38 100 54 99 72 98 91 94
Membrane-type EIA GDH 34 100 52 100 71 99 91 98
Well-type EIA toxins A/B 69 99 83 98 91 96 98 87
Membrane-type EIA toxins A/B 81 99 90 98 95 95 99 83
NAAT 46 100 64 100 80 99 94 96
Pooled estimates of sensitivity and speciﬁcity compared to cell cytotoxicity neutralization assay were used to calculate the predictive values.
CDI, Clostridium difﬁcile infection; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test; NPV, negative predictive value; PPV,
positive predictive value.
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neither GDH EIA nor toxin A/B EIA or NAAT can reliably be used as a
stand-alone test to diagnose CDI.
Because no single test is suitable to be used as a stand-alone test,
it is best to combine two tests in an algorithm in order to optimize
the diagnosis of CDI. The advantage of an algorithm is that tests can
be combined in such a way that the percentage of false-positive
results can be decreased. This can be done by testing all samples
with a ﬁrst test, then performing reﬂex testing on samples with a
positive ﬁrst test result only. The ﬁrst test should be a test that
reliably classiﬁes samples with a negative test result as non-CDI;
these samples will not be tested further. This ﬁrst test should
therefore be a test with a high NPV (i.e. a highly sensitive test).
Thus, in our case, this ﬁrst test can either be a GDH EIA or NAAT. The
choice between these two categories of assays can be made by each
individual laboratory. The second test should be a test with a high
PPV (i.e. a highly speciﬁc test), so that all samples with a positive
second test result can reliably be classiﬁed as CDI. Toxin A/B EIAs
can very well be used for this purpose, because besides being themost speciﬁc tests, these tests also have the advantage of detecting
free toxin. Thus, after application of a ﬁrst sensitive test (GDH EIA or
NAAT), the toxin A/B EIA can then be performed as a second step on
all samples that tested positive by NAAT or GDH EIA (Fig. 3(a)).
Samples with a positive second test result can be classiﬁed as CDI
likely to be present. However, samples with a ﬁrst positive test
result but a negative toxin A/B EIA need to be clinically evaluated.
Among these samples, CDI (with toxin levels below the threshold of
detection or a false-negative toxin A/B EIA result) or C. difﬁcile
carriage is possible.
A recent large study tried to establish the optimum diagnostic
algorithm for CDI [47]. In this study, 12 420 faecal samples were
tested by diverse commercial assays, TC and CCNA. The overall
performance of combined tests was superior to individual tests. The
combination of a NAAT (Xpert) and toxin A/B EIA (Techlab Tox A/B
II) was the optimal algorithm compared to the CCNA test, but the
GDH EIA (C. diff Chek-60)etoxin A/B EIA algorithm performed
almost identically [47]. These ﬁndings can be seen as a validation of
our more theoretical approach to establish the best testing strategy,
Step 1:
Highly sensitive test: NAAT or GDH EIA
Step 2:
Highly specific test:
Toxin A/B EIA
No further testing required:
CDI is unlikely to be 
present
CDI is likely to 
be present
Clinical 
evaluation: CDI 
or carriage of 
(toxigenic) C. 
difficile is 
possible
Negative test resultPositive test result
Positive test result Negative test result
Step 3 (optional):
Perform TC or NAAT (in 
case first test was a GDH 
EIA)
Step 1:
Highly sensitive test: GDH and Tox A/B 
EIA
No further testing 
required: CDI is likely to 
be present
CDI is unlikely 
to be present
Clinical 
evaluation: CDI 
or carriage of 
(toxigenic) C. 
difficile is 
possible
Both positiveBoth negative
Negative test result
No further testing 
required: CDI is 
unlikely to be present
GDH positive, Tox
A/B negative
Step 2 (optional):
NAAT or TC
Positive test result
(a)
(b)
Fig. 3. Recommended algorithms for CDI testing. (a) GDH or NAATeTox A/B algorithm. (b) GDH and Tox A/BeNAAT/TC algorithm. CDI, Clostridium difﬁcile infection; GDH, glutamate
dehydrogenase; NAAT, nucleic acid ampliﬁcation test; TC, toxigenic culture; Tox A/B, toxin A/B; EIA, enzyme immunoassay.
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alternatively GDH EIAetoxin A/B EIA, are two of the best algorithms
to diagnose CDI (Fig. 3(a)).
An alternative algorithm is to test simultaneously with both a
GDH and toxin A/B EIA. An assay is available that includes both
these targets in one system (C. diff Quik Chek Complete; Techlab),
but the sensitivity of the toxin component is unclear and may not
be as a high as some individual toxin EIAs (Tables 5e7). Samples
that test negative for both GDH and toxin A/B can reliably be
classiﬁed as non-CDI, while samples that test positive for both GDHand toxin A/B can be classiﬁed as CDI likely to be present. Samples
with a GDH-positive result but that are negative for toxin could
undergo reﬂex testing by NAAT to determine if a toxigenic C. difﬁcile
strain is present (Fig. 3(b)). Samples with a negative GDH result but
that are positive for toxin need to be retested, as this is an invalid
result. Only one study evaluating this kind of algorithm and
comparing it to a reference test was identiﬁed in the literature [45].
In this speciﬁc study, samples were screened by C. diff Quik Chek
Complete, and inconclusive results underwent reﬂex testing by
Illumigene. The overall sensitivity for this algorithm compared to
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overall sensitivity and speciﬁcity of this and the aforementioned
algorithm depend, however, on the individual assays that are
included.
Although we recommend the use of an algorithm for CDI testing
based on two rapid assays, every laboratory should also be able to
isolate C. difﬁcile, ideally via TC from selected samples, for two
reasons. First, TC offers the ability to perform molecular typing and
susceptibility testing on recovered isolates from positive samples
and can be used for outbreak investigations [75]. Second, samples
with a positive GDH EIA and/or NAAT but a negative toxin A/B EIA
may either be samples that tested falsely positive on GDH EIA/NAAT
or samples containing C. difﬁcile, but without detectable free toxin.
To be able to discern between these two conditions, a third-stage
reﬂex test to either a TC or NAAT or GDH (if not yet performed)
can be performed on samples with discordant results. For patients
with evidence of C. difﬁcile but negative toxin A/B EIA, clinical
evaluation is needed, and clinical considerations come into play to
determine a case as either positive or negative; these patients can
either be CDI patients with undetectable toxin levels, or false-
negative toxin A/B EIA results or potential carriers of toxigenic
C. difﬁcile. Although C. difﬁcile carriers may play an important role in
the spread of the disease [76,77], the indication for treating these
patients for CDI remains controversial. In addition, the need for
isolation precautions for these patients remains to be clariﬁed.
Therefore, performing TCs on these samples can be of importance
for epidemiologic purposes, but it is not yet a prerequisite for pa-
tient management.
The decision to treat CDI is ultimately a clinical decision, guided
by laboratory results. No tests are infallible, so it may be clinically
justiﬁed to treat a patient for CDI despite negative test results;
treatment should not be withheld on the basis of laboratory tests
alone. However, patients with toxin-negative specimens should
have alternative diagnoses considered and excluded; provided an
adequate testing strategy is followed, most patients with negative
results for CDI will truly not have this infection, and thus treatment
will be unnecessary.
Besides the question which assay or algorithm should be used
for CDI detection, another issue is the number of specimens per
patient that should be submitted for testing. Before the introduc-
tion of algorithms to diagnose CDI, lack of conﬁdence in the tests for
CDI detection (mainly toxin EIAs) led to the practice of multiple
sample submission. However, the diagnostic gain of repeat testing
within a 7-day period with both toxin A/B EIA and PCR was
demonstrated to be very low [78]. If one of the above proposed
algorithms is used, then the adequate NPV at low disease preva-
lence is based on original studies which did not test samples
repeatedly by index test and only once by reference test. This
adequate NPV indicates that routine submission of multiple sam-
ples after a ﬁrst negative test round has to be discouraged; these
samples can reliably be classiﬁed as non-CDI.
However, in cases of ongoing clinical suspicion during an
endemic situation, the submission of a repeat sample may be
justiﬁed, as these speciﬁc algorithms will have adequate PPVs even
in a low-prevalence situation.
In outbreak situations with a higher CDI prevalence in the tested
population, the NPV of the algorithm will fall. In such an outbreak
situation, submitting a repeat sample in case of ongoing clinical
suspicionwill be of value, as has been shown for toxin A/B EIA [79].
Testing for cure is not recommended, as patients can shed
spores and even toxins of C. difﬁcile for a prolonged time after
resolution of diarrhoea [80,81]. The infection can be considered
resolved when symptoms of diarrhoea have resolved.
Selection of which of submitted stool samples should be tested
for CDI is also important. Recognition of potential CDI cases may beburdensome, as it is increasingly being recognized that CDI is not
only acquired in healthcare facilities by patients with well-known
risk factors for the disease. In the Netherlands, C. difﬁcile was
relatively frequent among patients with diarrhoeal complaints in
general practice [82]. Community-onset CDI can affect all age
groups, and many patients do not have known risk factors [83,84].
A recent study showed that on a single day in Spain, two of every
three CDI episodes were underdiagnosed ormisdiagnosed owing to
nonsensitive tests (19.%) but more importantly to lack of suspicion
and request (47.6%) [85]. Especially for nonhospitalized patients
and younger patients, CDI tests were not requested [85]. This trend
was also seen in a study involving almost 500 hospitals in 20
countries across Europe: on two sampling days, 23% of samples
with a positive CDI test result were initially missed due to lack of
suspicion [73]. Hence, restricting testing to samples with a physi-
cian's request for CDI testing will lead to underdiagnosis.
Empirical testing of all unformed stool samples submitted to the
laboratory was shown to increase the diagnostic yield [73,86]. We
recommend testing all unformed faecal samples submitted to the
laboratory (except samples from children under age 3). In infants,
high rates of asymptomatic colonization with both toxigenic and
nontoxigenic strains have been described [87]. Even in the case of
toxin production, infants rarely develop clinical disease. However,
CDI can occur in infants and young children [88]. A recently
released policy statement from the American Academy of Pediatrics
recommends to test for CDI only if age-speciﬁc clinical criteria are
met [14]. According to their statement, searching for alternative
aetiologies should be performed even in the case of a positive CDI
test for children under 3 years of age. Concerning the problematic
interpretation of positive test results in this population, we indeed
recommend to limit testing of samples from children under age 3 to
samples with a physician's request only. Unformed stool samples of
children 3 years and older can be managed in the same way as
described above.
Clinical signs and symptoms are essential to CDI diagnosis.
Therefore, formed stool samples should not be tested for CDI, as
these do not meet the clinical criteria of CDI. However, sometimes
only solid parts of diarrhoeal faecesmay be collected and submitted
for C. difﬁcile testing. Local protocols therefore need to enable
C. difﬁcile testing on speciﬁc samples to take place. Also, an
exception has to be made for patients suspected of CDI who have
ileus. In these patients, a rectal swab can be used with adequate
sensitivity and speciﬁcity for (toxigenic) culture, NAAT or GDH EIA
[89,90]. The use of perirectal swabs for NAAT or GDH EIA testing
might also be an alternative in selected patient populations but
may depend on the presence of faecal staining of the swab [89e91].
However, the use of (peri)rectal swabs has not been evaluated for
toxin EIA, and therefore clinical judgement remains essential in
these cases to discern colonized patients from patients with CDI.
Recommendations
Sample selection
 We recommend that CDI testing should not be limited to sam-
ples with a speciﬁc physician's request. (Strong recommenda-
tion, high-quality evidence)
 We suggest that at least all submitted unformed stool samples
from patients 3 years or older should be tested for CDI. (Weak
recommendation, low-quality evidence)
 We suggest to limit testing of samples from children under age 3
to samples with a physician's request only. (Weak recommen-
dation, low-quality evidence)
 Formed stool samples should not be tested for CDI (except in
case of paralytic ileus). (Good practice statement)
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(toxigenic) culture, NAAT or GDH EIA. (Strong recommendation,
moderate-quality evidence)
Testing protocol
 The diagnosis of CDI should be based on clinical signs and
symptoms in combination with laboratory tests. Decision for
treatment for CDI is a clinical decision and may be justiﬁed even
if all laboratory tests are negative. (Good practice statement)
 We recommend against the use of a single rapid test as a stand-
alone test due to inadequate PPV in an endemic situation.
(Strong recommendation, moderate-quality evidence)
 We recommend the use of a 2-step algorithm (Fig. 3(A)). (Strong
recommendation, moderate-quality evidence)
 This algorithm should start with either NAAT or GDH EIA.
Samples with a negative ﬁrst test result can be reported as
negative. (Strong recommendation, moderate-quality evidence)
 Samples with a positive ﬁrst test result should be tested further
with a toxin A/B EIA. Samples with a positive second test results
can be reported as CDI-positive. (Strong recommendation,
moderate-quality evidence)
 An alternative algorithm is to screen samples with both a GDH
and toxin A/B EIA (Fig. 3(B)). Samples with concordant positive
or negative results can be reported as such. Samples with a
negative GDH result but positive for toxin need to be retested as
this is an invalid result. (Strong recommendation, moderate-
quality evidence)
 Samples with a positive ﬁrst test result and negative second test
result (Fig. 3(A)) and samples with a GDH-positive test result but
negative toxin A/B test result (Fig. 3(B)) may represent samples
with CDI or C. difﬁcile carriage andmay optionally be tested with
TC or NAAT (if not performed yet). (Weak recommendation,
moderate-quality evidence)
 We recommend to perform TC and molecular typing of recov-
ered isolates in case of outbreak situations. (Good practice
statement)
Repeated testing
 Repeated testing after a ﬁrst positive sample during the same
diarrhoeal episode is not recommended in an endemic situation.
(Strong recommendation, moderate-quality evidence)
 Repeated testing after a ﬁrst negative sample during the same
diarrhoeal episode may be useful in selected cases with ongoing
clinical suspicion during an epidemic situation or in cases with
high clinical suspicion during endemic situations. (Strong
recommendation, moderate-quality evidence)
 A test of cure is not recommended. (Good practice statement)
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